{
  "company": {
    "name": "DTx Pharma",
    "website": "https://dtxpharma.com/",
    "record": "https://startuphistory.org/c/dtxpharma.com"
  },
  "status": null,
  "history_since": "2018-08-06T13:39:14.000Z",
  "baseline": {
    "snapshot_id": "6268e053774d7038c6eec647b65587d1373fef4a02ada79aa709fadf1b316c8d",
    "observed_at": "2018-08-06T13:39:14.000Z",
    "headline": null,
    "description": "Our Mission DTx Pharma is developing technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across most therapeutic areas. Contact us for more informa",
    "evidence": "https://web.archive.org/web/20180806133914/http://dtxpharma.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T13:38:42.157Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2021-01-06T17:03:29.000Z",
      "variants": [
        {
          "headline": "Enabling Precision Medicine",
          "subhead": "At DTx we’re inspired to improve the lives of patients suffering from rare and chronic diseases worldwide by introducing next-generation, safe and effective medicines based on fatty acid motifs that d",
          "observed_at": "2020-06-07T06:27:51.000Z",
          "evidence": "https://web.archive.org/web/20200607062751/https://dtxpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Enabling Precision Medicine",
          "subhead": "At DTx we’re inspired to improve the lives of patients suffering from rare and chronic diseases worldwide by introducing next-generation, safe and effective medicines based on fatty acid motifs that d",
          "observed_at": "2021-01-06T17:03:29.000Z",
          "evidence": "https://web.archive.org/web/20210106170329/https://dtxpharma.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Enabling Precision Medicine",
      "subhead": "At DTx we’re inspired to improve the lives of patients suffering from rare and chronic diseases worldwide by introducing next-generation, safe and effective medicines based on fatty acid motifs that d",
      "from": "2020-06-07T06:27:51.000Z",
      "to": "2021-01-06T17:03:29.000Z",
      "captures": 2,
      "evidence": "https://web.archive.org/web/20210106170329/https://dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2020-06-07T06:27:51.000Z",
          "to": "2021-01-06T17:03:29.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2025-02-20T20:29:52.000Z",
      "variants": [
        {
          "headline": "Taking RNA Medicines to New Heights",
          "subhead": "At DTx, we are a group of flexible, innovative thinkers who are determined to solve one of the biggest challenges limiting the development of genetic medicines.",
          "observed_at": "2021-07-09T01:06:40.000Z",
          "evidence": "https://web.archive.org/web/20210709010640/https://dtxpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Taking RNA Medicines to New Heights",
          "subhead": "At DTx, we are a group of flexible, innovative thinkers who are determined to solve one of the biggest challenges limiting the development of genetic medicines.",
          "observed_at": "2022-09-26T08:48:11.000Z",
          "evidence": "https://web.archive.org/web/20220926084811/https://dtxpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Breaking open new therapeutic areas for RNA medicines",
          "subhead": "DTx Pharma is a clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics.",
          "observed_at": "2023-01-27T23:48:39.000Z",
          "evidence": "https://web.archive.org/web/20230127234839/https://dtxpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Breaking open new therapeutic areas for RNA medicines",
          "subhead": "DTx Pharma is a clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics.",
          "observed_at": "2024-12-03T15:21:43.000Z",
          "evidence": "https://web.archive.org/web/20241203152143/https://dtxpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Breaking open new therapeutic areas for RNA medicines",
          "subhead": "DTx Pharma is a clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics.",
          "observed_at": "2025-02-20T20:29:52.000Z",
          "evidence": "https://web.archive.org/web/20250220202952/https://dtxpharma.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Breaking open new therapeutic areas for RNA medicines",
      "subhead": "DTx Pharma is a clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics.",
      "from": "2021-07-09T01:06:40.000Z",
      "to": "2025-02-20T20:29:52.000Z",
      "captures": 5,
      "evidence": "https://web.archive.org/web/20250220202952/https://dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2021-07-09T01:06:40.000Z",
          "to": "2025-02-20T20:29:52.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-06-14T19:12:10.000Z",
      "variants": [
        {
          "headline": "BYLO TO O PRSA",
          "subhead": null,
          "observed_at": "2026-02-06T22:25:35.000Z",
          "evidence": "https://web.archive.org/web/20260206222535/http://www.dtxpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "BYLO TO O PRSA",
          "subhead": null,
          "observed_at": "2026-06-14T19:12:10.000Z",
          "evidence": "https://web.archive.org/web/20260614191210/http://www.dtxpharma.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "BYLO TO O PRSA",
      "subhead": null,
      "from": "2026-02-06T22:25:35.000Z",
      "to": "2026-06-14T19:12:10.000Z",
      "captures": 2,
      "evidence": "https://web.archive.org/web/20260614191210/http://www.dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2026-02-06T22:25:35.000Z",
          "to": "2026-06-14T19:12:10.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T13:38:42.157Z",
      "variants": [
        {
          "headline": "Reimagining medicine, together.",
          "subhead": "For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medic",
          "observed_at": "2026-11-05T13:38:42.157Z",
          "evidence": "https://www.novartis.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Reimagining medicine, together.",
      "subhead": "For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medic",
      "from": "2026-11-05T13:38:42.157Z",
      "to": "2026-11-05T13:38:42.157Z",
      "captures": 1,
      "evidence": "https://www.novartis.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "on": "2026-11-05T13:38:42.157Z"
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-10b83914b659f851b563d212775017c9741e7961a51dea4add12f10d2a671c3b:c99d669e79ad05262790ce8dbcd1b7414950235ebfe4e7c1000b73c4bacfcfa1:headline:0e67f48bca5d0790",
      "before_evidence": "https://web.archive.org/web/20190818091254/http://dtxpharma.com:80/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Our Mission” to “Enabling Precision Medicine”.",
      "between": {
        "from": "2019-08-18T09:12:54.000Z",
        "to": "2020-06-07T06:27:51.000Z"
      },
      "evidence": "https://web.archive.org/web/20200607062751/https://dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 2,
      "id": "page-10b83914b659f851b563d212775017c9741e7961a51dea4add12f10d2a671c3b:c99d669e79ad05262790ce8dbcd1b7414950235ebfe4e7c1000b73c4bacfcfa1:hiring:20dd4c09cc4ab0aa",
      "before_evidence": "https://web.archive.org/web/20190818091254/http://dtxpharma.com:80/",
      "before_evidence_kind": "internet_archive",
      "kind": "hiring",
      "label": "Hiring",
      "summary": "Added a careers page.",
      "between": {
        "from": "2019-08-18T09:12:54.000Z",
        "to": "2020-06-07T06:27:51.000Z"
      },
      "evidence": "https://web.archive.org/web/20200607062751/https://dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-careers-page"
    },
    {
      "n": 3,
      "id": "page-3748146cbebcc57be385589b784d73e5c2b2f6c84e03d8e9307702f7bb91c5b0:bf83da2f35159d8c6df599d736c6f5a73c61d0313b934aeca1abe22771a99afa:headline:cf767dbf9e5e2dc2",
      "before_evidence": "https://web.archive.org/web/20210106170329/https://dtxpharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Enabling Precision Medicine” to “Taking RNA Medicines to New Heights”.",
      "between": {
        "from": "2021-01-06T17:03:29.000Z",
        "to": "2021-07-09T01:06:40.000Z"
      },
      "evidence": "https://web.archive.org/web/20210709010640/https://dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 4,
      "id": "page-3748146cbebcc57be385589b784d73e5c2b2f6c84e03d8e9307702f7bb91c5b0:bf83da2f35159d8c6df599d736c6f5a73c61d0313b934aeca1abe22771a99afa:investors:45a529cb708849f0",
      "before_evidence": "https://web.archive.org/web/20210106170329/https://dtxpharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "investors",
      "label": "Investors",
      "summary": "Now shows investor logos: investor-access-Biotechn ology, investor-cormorant, investor-Janus-Henderson, investor-lilly, investor-logos-capital, investor-RA-capital, investor-logos-surveyor and investor-viva.",
      "between": {
        "from": "2021-01-06T17:03:29.000Z",
        "to": "2021-07-09T01:06:40.000Z"
      },
      "evidence": "https://web.archive.org/web/20210709010640/https://dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-investor-logos"
    },
    {
      "n": 5,
      "id": "page-92bdef24b0781ac0aea2878dc01b8d40f9123c81042786346f5875b958fb5500:d67ee4076cee89d8e2322b74d3571f74c5bcccebc21be72d9532f8356a7bdbdd:headline:03bab04fc807234e",
      "before_evidence": "https://web.archive.org/web/20220926084811/https://dtxpharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Taking RNA Medicines to New Heights” to “Breaking open new therapeutic areas for RNA medicines”.",
      "between": {
        "from": "2022-09-26T08:48:11.000Z",
        "to": "2023-01-27T23:48:39.000Z"
      },
      "evidence": "https://web.archive.org/web/20230127234839/https://dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 6,
      "id": "page-ac7e2d90bf5ae470c713b643db8e55c8f55e9ba043fb8afb484c8adbafbe1454:ff12d651e3abc01fa9c085bef0a3527196248ce84d93fad7eb629262d649d3c2:headline:b4dfa7822449bbf9",
      "before_evidence": "https://web.archive.org/web/20250220202952/https://dtxpharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Breaking open new therapeutic areas for RNA medicines” to “BYLO TO O PRSA”.",
      "between": {
        "from": "2025-02-20T20:29:52.000Z",
        "to": "2026-02-06T22:25:35.000Z"
      },
      "evidence": "https://web.archive.org/web/20260206222535/http://www.dtxpharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 7,
      "id": "page-e8385fd368d88950ecd5b2e3c5e3ac1706ca30402ae308c4bb879af5e4a340f6:0288e1389e8912c55044218dc6c09d75d41435e2fe5b3ba4ae16a25fdb17f849:headline:c9a35c3e7de1a84d",
      "before_evidence": "https://web.archive.org/web/20260614191210/http://www.dtxpharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “BYLO TO O PRSA” to “Reimagining medicine, together.”.",
      "between": {
        "from": "2026-06-14T19:12:10.000Z",
        "to": "2026-11-05T13:38:42.157Z"
      },
      "evidence": "https://www.novartis.com/",
      "evidence_kind": "live_capture",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “DTx Pharma” company record, https://startuphistory.org/c/dtxpharma.com"
}